DeAnna Henderson1, Danielle Frieson1, Jeffrey Zuber2, Solomon S Solomon3. 1. Endocrinology Division, University of Tennessee Health Science Center, Memphis, Tennessee. 2. Department of Preventive Medicine, University of Tennessee Health Science Center, Memphis, Tennessee. 3. Endocrinology Division, University of Tennessee Health Science Center, Memphis, Tennessee; Research Service (151), Veterans Affairs Medical Center-Memphis, Memphis, Tennessee. Electronic address: ssolomon@uthsc.edu.
Abstract
BACKGROUND: Metformin (MF), a diabetic drug, has antineoplastic activity as adjuvant therapy for breast cancer and prostate cancer. MF is thought to work via inhibition of mammalian target of rapamycin and activation of p53 and liver kinase B1 via adenosine 5'-monophosphate-activated protein kinase. We investigated survival, recurrences and metastasis in patients with type 2 diabetes mellitus (DM2) along with colorectal cancer (CC) or lung cancer (LC) taking MF using the electronic medical record in Memphis Veterans Affairs Medical Center (colon, n = 202; lung, n = 180). MATERIALS AND METHODS: Patients with CC or LC and DM2 on MF were compared to controls taking any medication except MF. Recurrences, metastases, secondary cancers, survival and carcinoembryonic antigen levels were compared using t test and chi-squared test. Inclusion criteria were based on MF use, CC or LC diagnosis and DM2. RESULTS: For CC, the MF group noted fewer deaths (48% versus 76%, P < 0.001), recurrences (4% versus 19%, P = 0.002), metastases (23% versus 46%, P = 0.001), better 5-year survival rates (57% versus 37%, P = 0.004), overall survival years (5.7 versus 4.1, P = 0.007) and greater carcinoembryonic antigen decrease (72% versus 47%, P = 0.015). MF was associated with improved 5-year survival rates (29% versus 15%, P = 0.023) and overall survival years (3.4 versus 1.8, P < 0.001) in LC. CONCLUSIONS: Our study shows that MF therapy is associated with significantly better prognosis in patients with CC and improved survival in LC. Patients with CC on MF had fewer recurrences and metastases. Differences in metabolic pathways between CC and LC likely account for the differences in the effect of MF. Published by Elsevier Inc.
BACKGROUND:Metformin (MF), a diabetic drug, has antineoplastic activity as adjuvant therapy for breast cancer and prostate cancer. MF is thought to work via inhibition of mammalian target of rapamycin and activation of p53 and liver kinase B1 via adenosine 5'-monophosphate-activated protein kinase. We investigated survival, recurrences and metastasis in patients with type 2 diabetes mellitus (DM2) along with colorectal cancer (CC) or lung cancer (LC) taking MF using the electronic medical record in Memphis Veterans Affairs Medical Center (colon, n = 202; lung, n = 180). MATERIALS AND METHODS:Patients with CC or LC and DM2 on MF were compared to controls taking any medication except MF. Recurrences, metastases, secondary cancers, survival and carcinoembryonic antigen levels were compared using t test and chi-squared test. Inclusion criteria were based on MF use, CC or LC diagnosis and DM2. RESULTS: For CC, the MF group noted fewer deaths (48% versus 76%, P < 0.001), recurrences (4% versus 19%, P = 0.002), metastases (23% versus 46%, P = 0.001), better 5-year survival rates (57% versus 37%, P = 0.004), overall survival years (5.7 versus 4.1, P = 0.007) and greater carcinoembryonic antigen decrease (72% versus 47%, P = 0.015). MF was associated with improved 5-year survival rates (29% versus 15%, P = 0.023) and overall survival years (3.4 versus 1.8, P < 0.001) in LC. CONCLUSIONS: Our study shows that MF therapy is associated with significantly better prognosis in patients with CC and improved survival in LC. Patients with CC on MF had fewer recurrences and metastases. Differences in metabolic pathways between CC and LC likely account for the differences in the effect of MF. Published by Elsevier Inc.
Entities:
Keywords:
Colon cancer; Lung cancer; Metformin; Type 2 diabetes mellitus
Authors: Jenny J Lin; Emily J Gallagher; Keith Sigel; Grace Mhango; Matthew D Galsky; Cardinale B Smith; Derek LeRoith; Juan P Wisnivesky Journal: Am J Respir Crit Care Med Date: 2015-02-15 Impact factor: 21.405
Authors: K Rapp; J Schroeder; J Klenk; H Ulmer; H Concin; G Diem; W Oberaigner; S K Weiland Journal: Diabetologia Date: 2006-03-24 Impact factor: 10.122
Authors: Preet Paul Singh; Qian Shi; Nathan R Foster; Axel Grothey; Suresh G Nair; Emily Chan; Anthony F Shields; Richard M Goldberg; Sharlene Gill; Morton S Kahlenberg; Frank A Sinicrope; Daniel J Sargent; Steven R Alberts Journal: Oncologist Date: 2016-11-23
Authors: Jin Sun Lee; Ji Young Sul; Jun Beom Park; Myung Sun Lee; Eun Young Cha; Young Bok Ko Journal: Int J Mol Med Date: 2019-03-05 Impact factor: 4.101
Authors: Suzan Brancher; Nathalie C Støer; Elisabete Weiderpass; Ronald A M Damhuis; Tom B Johannesen; Edoardo Botteri; Trond-Eirik Strand Journal: Br J Cancer Date: 2020-12-02 Impact factor: 7.640